Literatür Detay Bilgisi
Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin's lymphoma after responding to first-line rituximab plus chemotherapy.
Yazarlar : Hornberger J, Chien R, Friedmann M, Han L, Shewade A, Satram-Hoang S, Reyes C.
Yayın : Leuk Lymphoma.
Yayın Yılı : 2012
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22591119
Konu : Lenfoma
Literatür İçeriği :
Abstract
Abstract A recent phase III trial demonstrated maintenance rituximab (R) therapy after response to first-line treatment with rituximab plus chemotherapy (R-chemo) increases progression-free survival (PFS) for follicular non-Hodgkin's lymphoma (f-NHL). A cost-effectiveness analysis of R-maintenance versus observation was conducted from a U.S. payer perspective to estimate PFS and overall survival (OS) over a representative patient's lifetime. Primary outcomes were cost per life-year gained (LYG) and cost per quality-adjusted life-year (QALY) gained. Compared with observation, R-maintenance increased mean PFS by 1.50 years, OS by 1.21 years, and QALYs gained by 1.11 years. Incremental cost of maintenance therapy was $38,545. The costs per LYG and QALY gained were $31,934 and $34,842, respectively. Within the limitations of modeling long-term outcomes, R-maintenance therapy in patients who received R-chemo for previously untreated f-NHL compared with observation alone after R-chemo for first-line treatment for f-NHL is cost-effective from the U.S. payer perspective.Konusu Aynı Olan Diğer Materyaller
| Sunumlar | Videolar | Olgu Tartışması |
